89bio to Showcase Pegozafermin Trial Insights at Major Conference
89bio Presents Key Findings from ENLIVEN Phase 2b Trial
89bio, Inc. (NASDAQ: ETNB), a biopharmaceutical company committed to developing innovative treatments for liver and cardiometabolic diseases, has exciting news. The company will present new analyses from its Phase 2b ENLIVEN trial, which assesses the efficacy of pegozafermin in patients suffering from metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, during the esteemed AASLD The Liver Meeting® 2024.
Poster Presentation Highlights
At the upcoming meeting scheduled for November, four poster presentations will spotlight significant findings from the ENLIVEN trial.
Key Abstracts and Presenting Authors
The abstracts include:
- Biomarker response in MASH patients with high-risk baseline FAST scores: Findings by Naim Alkhouri, MD, will be revealed on November 15 from 8:00 AM to 5:00 PM PST.
- Pegozafermin's impact on cirrhosis progression: A post-hoc analysis presented by Jörn M. Schattenberg, MD, on November 15 from 8:00 AM to 5:00 PM PST.
- Machine Learning Insights: An analysis by Oliver Mansbach, BA/BS, scheduled for November 16 from 8:00 AM to 5:00 PM PST.
- Diagnostic potential of FAST and AGILE3+ scores: Presented again by Naim Alkhouri, MD, on November 16 from 8:00 AM to 5:00 PM PST.
Understanding MASH and Its Treatment
Metabolic dysfunction-associated steatohepatitis (MASH), a serious form of liver disease, is characterized by liver fat accumulation, inflammation, and potential fibrosis. With rising numbers projected to affect millions, it is crucial to target treatments aimed at improving liver health and reducing complications such as cirrhosis and cardiovascular implications.
Treating advanced fibrosis requires a multidisciplinary approach, emphasizing the importance of timely intervention to prevent complications. MASH's complex nature necessitates effective therapeutic strategies to significantly enhance patient outcomes.
Insights into the ENLIVEN Trial
The ENLIVEN trial, a pivotal Phase 2b study, was meticulously designed to evaluate the safety and efficacy of weekly or biweekly pegozafermin dosing. Involving 192 participants, the study's primary goals focused on resolution rates of MASH and improvements in fibrosis staging after 24 weeks.
Results demonstrated remarkable efficacy, achieving high statistical significance—particularly with the 30 mg QW and 44 mg Q2W dosing regimens. These findings significantly contribute to understanding pegozafermin's therapeutic potential, with published results available for further exploration.
The Mechanism of Pegozafermin
Pegozafermin, an engineered glycoPEGylated analog of fibroblast growth factor 21, aims to combat MASH and related hypertriglyceridemia. Clinical trials have highlighted its ability to not only reduce triglyceride levels but also improve insulin sensitivity and liver inflammation, showcasing its broad therapeutic profile.
About 89bio and Future Directions
Headquartered in San Francisco, 89bio is dedicated to creating and advancing best-in-class solutions for individuals struggling with liver and metabolic diseases. With an active focus on moving pegozafermin swiftly through clinical trials, the company exemplifies commitment in an area desperately needing innovation.
The firm is pursuing exciting developments not only in MASH but also in related indications through ongoing Phase 3 trials, positioning itself favorably within the biopharmaceutical landscape.
Frequently Asked Questions
What is the ENLIVEN trial?
The ENLIVEN trial is a Phase 2b study evaluating the safety and effectiveness of pegozafermin in treating patients with metabolic dysfunction-associated steatohepatitis (MASH).
What are the key findings from the recent posters at AASLD?
The posters showcase various analyses, including biomarker responses, potential impacts on fibrosis progression, and the use of machine learning in treatment assessments.
What is the significance of pegozafermin?
Pegozafermin is designed to address the complex issues of MASH and severe hypertriglyceridemia, demonstrating promising results in improving liver function and metabolic parameters.
How does MASH affect patients?
MASH can lead to serious liver complications, including cirrhosis and hepatocellular carcinoma, greatly affecting patients' overall health and survival.
Where can I find more information about 89bio?
For detailed insights, you may contact 89bio directly or visit their official website.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Nathan Cherry's New Role at Intrepid Drives Upstream Growth
- Telenor Group's Q3 2024 Results: Join Us for Insights
- Investors Urged to Act: Class Actions for EXTR, PDD, CXM, SYM
- Enhancements to Protective Aspirations Variable Annuity Product
- HSG Laser Enhances Production with New Automation Solutions
- Ress Life Investments A/S Reveals Latest Net Asset Value Insights
- Bitcoin's Rally Potential: Factors to Watch Before the Election
- Kestra Holdings Partners with Stone Point Capital for Growth
- Anthony Pompliano Shares Insights on Tesla's Influence on Stablecoins
- Amazon Teams Up with Databricks to Revolutionize AI Cost Savings
Recent Articles
- Olive My Pickle Celebrates Launch of The Pickle Factory Store
- Immuneering Gains Orphan Drug Status for Groundbreaking Cancer Therapy
- Discover Godiva's Premium Heritage Collection of Chocolates
- Workhorse W56 Launches into Production with Key Certifications
- BioVie Advances Terlipressin Patents and Clinical Innovations
- DeepHow Enhances Workforce Training via SAP Store Integration
- Join scPharmaceuticals' KOL Webinar to Learn About FUROSCIX
- RTI International Collaborates with Codetta Bio for Healthcare Advancements
- Junee Limited Secures $100M Partnership for AI Advancement
- ETC's Strong Sales Growth in Latest Fiscal Quarter
- Carmela Coffee Expands with New Café Location in Florida
- Newton Golf's Strategic Expansion into Japan's Golf Market
- Hudson Technologies Plans Conference Call for Q3 Financial Insights
- Vir Biotechnology Set to Share Groundbreaking Hepatitis Trial Results
- Galecto Enhances Leadership with Dr. Amy Wechsler's Appointment
- BMO Elevates S&P Global's Stock Target Amid Strong Performance
- HeartCore Teams Up with NTT Data for Enhanced Website Solutions
- Comprehensive Overview on Celsius Holdings' Market Position
- CVR Partners Plans to Unveil Third Quarter Financials Soon
- Alto Ingredients Reports Exciting Developments in Production
- Needham Adjusts ViaSat Stock Target Amid Competition and Supply Issues
- Yoshiharu Global Partners with Chengdu Octaday for Growth
- BMO Adjusts Constellation Brands Target Price, Maintains Rating
- Banzai Partners with MZ Group to Enhance Investor Relations
- Expion360 Gears Up for LD Micro Main Event with New Insights
- Apple's Ambitious Car Project Ends Amidst Competition Shifts
- UnitedHealth Group's Q3 Performance: Insights and Analysis
- Citigroup Faces Challenges as Profit Declines in Recent Quarter
- Progressive Insurance Reports Impressive Q3 2024 Financials
- Statkraft AS Advances Sustainability with New Green Bonds
- Ciena Corp's Future Looks Bright Despite Recent Downgrade
- Investigation Looms Over ADMA Biologics Amid Auditor Departure
- Progressive Beats Earnings Estimates with Strong Revenue Growth
- Serious Concerns for Acadia Healthcare Following Stock Plummet
- Coeptis Therapeutics to Showcase Innovations at Key Conferences
- DT Midstream to Reveal Q3 Financial Outcomes and Call Schedule
- Investors Rally Around Serra Ventures' Ag & Food Tech Fund II
- Lucid Diagnostics Achieves Key Patent Milestone for Cancer Test
- CareDx and JD.com: Pre-Market Declines Raise Investor Concerns
- Discover SuperStix™: The New Organic Hydration Revolution
- Tyfone Introduces Payfinia Inc. to Transform Payment Solutions
- Galileo Emerges as a Leader in AI Evaluation with New Funding
- Expert Analysts Review High Yield Dividend Stocks Today
- UBS Continues Positive Outlook for Freeport-McMoRan Amid Setbacks
- Exciting Opportunities for Teams in the Future City Challenge
- Rockefeller Asset Management Launches RSMC for SMID Cap Investors
- Jim Cramer Champions Uranium Energy Corp: A Look at Stocks
- Fonoa Enhances Indirect Tax Compliance Solutions with PwC Deal
- MDVIP Enhances Patient Care with New Practices in NC
- Innovation Beverage Group Sets Sights on Global Horizons in Beverages